Premium
Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck
Author(s) -
Hong Min Hee,
Kim Chang Gon,
Koh Yoon Woo,
Choi Eun Chang,
Kim Jinna,
Yoon Sun Och,
Kim Hye Ryun,
Cho Byoung Chul
Publication year - 2018
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24933
Subject(s) - vinorelbine , medicine , head and neck cancer , cisplatin , chemotherapy , oncology , salivary gland cancer , phases of clinical research , cancer , clinical endpoint , salivary gland , clinical trial
Abstract Background The purpose of this study was to investigate the efficacy and safety of vinorelbine plus cisplatin chemotherapy in patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Methods In this single‐arm phase II study, patients with recurrent and/or metastatic salivary gland cancer were treated with i.v. vinorelbine (25 mg/m 2 ) on days 1 and 8 plus cisplatin (80 mg/m 2 ) on day 1 every 3 weeks for 4 or 6 cycles. The primary endpoint was the objective response rate. Progression‐free survival (PFS), overall survival (OS), and adverse events were also assessed. Results Between September 2008 and November 2014, 40 patients with recurrent and/or metastatic salivary gland cancer received vinorelbine plus cisplatin chemotherapy. The objective response rate was 35.0%, including 1 complete response. Median PFS and OS rates were 6.3 months and 16.9 months, respectively. No treatment‐related deaths occurred. Conclusion Administering vinorelbine plus cisplatin chemotherapy to patients with recurrent and/or metastatic salivary gland cancers is safe and effective.